Commissioning summary
Treatment
Evidence and costs
-
Using maintenance or combination treatments leads to people experiencing fewer severe asthma exacerbations and fewer hospital admissions. This is compared with short-acting beta 2 agonist (SABA)-only regimens.
-
The impact of 10,000 people switching from SABA-only regimens to maintenance and reliever therapy (MART) would be:
-
an additional cost of £340,000 per year
-
a net budget impact of £180,000 per year
-
1,133 fewer GP visits per year
-
144 fewer people presenting at A&E per year
-
80 fewer people being admitted to hospital per year.
-
-
Reducing reliance on SABA aerosol inhalers will also support your Integrated Care Board's local green plan.
Barriers
-
Healthcare professionals may need further support to understand the benefits of maintenance or combination treatments.
-
Some people may need additional support to switch to a new regimen. NICE's guideline on shared decision making can help support these discussions. Other tools are also available in the section on resources to share with your network.
This page was last updated: